Emergent BioSolutions Reports 30% Revenue Decline and 90% Drop in Net Income for Q1 2026

Emergent BioSolutions Inc. reported a significant decline in financial performance for the first quarter of 2026, with total revenues of $156.1 million, down 30% from $222.2 million in the same period last year. The decrease was primarily driven by a 35% drop in Medical Countermeasures (MCM) product sales, which fell to $101.8 million from $156.6 million. The company also experienced a decline in commercial product sales, which decreased by 5% to $42.9 million, and a 51% reduction in contracts and grants revenue, which totaled $6.4 million. Net income for the quarter was $6.8 million, a sharp decline of 90% compared to $68.0 million in the prior year.

Operating expenses also saw a reduction, decreasing by 15% to $145.6 million, down from $172.3 million. This reduction was attributed to lower costs associated with product sales, research and development, and selling, general, and administrative expenses. The cost of product and services sales decreased by 19% to $72.0 million, reflecting a decrease in sales volume and associated costs. Despite these reductions, the company reported an operating income of $10.5 million, down 79% from $49.9 million in the previous year.

Emergent BioSolutions has been actively restructuring its operations, which included the acquisition of exclusive commercial rights for KLOXXADO® Nasal Spray in January 2025. The company has also been focusing on its product portfolio, which includes 11 products aimed at addressing public health threats. As of March 31, 2026, the company had 51,596,296 shares of common stock outstanding and had authorized a share repurchase program of up to $50 million, with $9.1 million utilized for repurchases during the quarter.

Looking ahead, Emergent BioSolutions anticipates continued variability in its financial results due to the timing of production and deliveries, as well as the nature of its business, which involves large-scale bundles of products and services. The company has indicated that it will continue to seek government contracts and funding for its medical countermeasures, which are critical for its revenue generation. The outlook remains cautious, with management emphasizing the need for ongoing evaluation of market conditions and operational efficiencies to navigate the challenges ahead.